Expression of C-Kit and PDGFRα in Epithelial Ovarian Tumors and Tumor Stroma

Overview

Journal Oncol Lett

Specialty Oncology

Date 2012 Jun 29

PMID 22740913

Citations 6

Authors

Cunjian Yi

Li Li

Keming Chen

Shengrong Lin

Xiangqiong Liu

Affiliations

Soon will be listed here.

Abstract

The purpose of this study was to investigate the expression of c-Kit and platelet-derived growth factor receptor α (PDGFRα) in epithelial ovarian tumor cells and tumor stroma. The expression of c-Kit and PDGFRα in 71 malignant or benign epithelial ovarian tumor tissues and 20 normal ovarian tissues was evaluated by immunohistochemical staining. The expression of c-Kit and PDGFRα in 71 malignant epithelial ovarian tumors and tumor stroma tissue samples was analyzed. A significant increase (P<0.01) of c-Kit expression was observed in malignant ovarian tumors (50.7%) when compared to normal ovarian tissues (10.0%) or benign ovarian tumors (20.0%). The PDGFRα expression rate in malignant ovarian tumors (63.4%) was also significantly higher (P<0.01) than that in normal ovarian tissues (15.0%) or benign ovarian tumors (25.0%). c-Kit was expressed in only 4.2% of the tumor stroma samples, which was significantly lower than the expression of malignant ovarian tumors (P<0.01), whereas the PDGFRα expression in tumor stroma (87.3%) was significantly higher than that of the malignant ovarian tumors (P<0.01). The expression levels of c-Kit and PDGFRα are higher in the malignant ovarian tumors than in the benign ovarian tumors or normal tissues. In the malignant ovarian tumor stroma, c-Kit expression is low and PDGFRα expression is high, and the differential changes of c-kit and PDGFRα suggest distinct roles in ovarian cancer.

Citing Articles

Characterization of stem cell and cancer stem cell populations in ovary and ovarian tumors.

Parte S, Batra S, Kakar S J Ovarian Res. 2018; 11(1):69.

PMID: 30121075 PMC: 6098829. DOI: 10.1186/s13048-018-0439-3.

Progression inference for somatic mutations in cancer.

Peterson L, Kovyrshina T Heliyon. 2017; 3(4):e00277.

PMID: 28492066 PMC: 5415494. DOI: 10.1016/j.heliyon.2017.e00277.

Establishment of an orthotopic transplantation tumor model in nude mice using a drug-resistant human ovarian cancer cell line with a high expression of c-Kit.

Yi C, Zhang L, Li L, Liu X, Ling S, Zhang F Oncol Lett. 2014; 8(6):2611-2615.

PMID: 25364436 PMC: 4214472. DOI: 10.3892/ol.2014.2537.

A panel of overexpressed proteins for prognosis in esophageal squamous cell carcinoma.

Shang L, Liu H, Hao J, Jiang Y, Shi F, Zhang Y PLoS One. 2014; 9(10):e111045.

PMID: 25337715 PMC: 4206450. DOI: 10.1371/journal.pone.0111045.

Expression and significance of transforming growth factor-β1 in epithelial ovarian cancer and its extracellular matrix.

Chen K, Wei H, Ling S, Yi C Oncol Lett. 2014; 8(5):2171-2174.

PMID: 25295105 PMC: 4186593. DOI: 10.3892/ol.2014.2448.

References

Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D . Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003; 111(9):1287-95. PMC: 154450. DOI: 10.1172/JCI17929. View

Singer G, Schraml P, Belgard C, Raggi A, Dirnhofer S, Went P . KIT in ovarian carcinoma: disillusion about a potential therapeutic target. J Natl Cancer Inst. 2003; 95(13):1009-10. DOI: 10.1093/jnci/95.13.1009-a. View

Baranowska-Kortylewicz J, Abe M, Pietras K, Kortylewicz Z, Kurizaki T, Nearman J . Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy. Cancer Res. 2005; 65(17):7824-31. PMC: 1363769. DOI: 10.1158/0008-5472.CAN-04-3991. View

Malaise M, Steinbach D, Corbacioglu S . Clinical implications of c-Kit mutations in acute myelogenous leukemia. Curr Hematol Malig Rep. 2010; 4(2):77-82. DOI: 10.1007/s11899-009-0011-8. View

Schneider B, Kalemkerian G, Ramnath N, Kraut M, Wozniak A, Worden F . Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer. Clin Lung Cancer. 2010; 11(4):223-7. DOI: 10.3816/CLC.2010.n.028. View

Schmandt R, Broaddus R, Lu K, Shvartsman H, Thornton A, Malpica A . Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer. 2003; 98(4):758-64. DOI: 10.1002/cncr.11561. View

Matei D, Chang D, Jeng M . Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin Cancer Res. 2004; 10(2):681-90. DOI: 10.1158/1078-0432.ccr-0754-03. View

Dabrow M, Francesco M, McBrearty F, Caradonna S . The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynecol Oncol. 1998; 71(1):29-37. DOI: 10.1006/gyno.1998.5121. View

Yu J, Moon A, Kim H . Both platelet-derived growth factor receptor (PDGFR)-alpha and PDGFR-beta promote murine fibroblast cell migration. Biochem Biophys Res Commun. 2001; 282(3):697-700. DOI: 10.1006/bbrc.2001.4622. View

10.

Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T . ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature. 2010; 467(7317):849-53. PMC: 2955195. DOI: 10.1038/nature09409. View

11.

Tonary A, Macdonald E, Faught W, Senterman M, Vanderhyden B . Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis. Int J Cancer. 2000; 89(3):242-50. DOI: 10.1002/1097-0215(20000520)89:3<242::aid-ijc6>3.0.co;2-6. View

12.

Apte S, Bucana C, Killion J, Gershenson D, Fidler I . Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecol Oncol. 2004; 93(1):78-86. DOI: 10.1016/j.ygyno.2003.12.041. View

13.

Parrott J, Kim G, Skinner M . Expression and action of kit ligand/stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer. Biol Reprod. 2000; 62(6):1600-9. DOI: 10.1095/biolreprod62.6.1600. View

14.

Lux M, Rubin B, Biase T, Chen C, Maclure T, Demetri G . KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol. 2000; 156(3):791-5. PMC: 1876850. DOI: 10.1016/S0002-9440(10)64946-2. View

15.

Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M, Oberg K . Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res. 1993; 53(19):4550-4. View

16.

Arber D, Tamayo R, Weiss L . Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol. 1998; 29(5):498-504. DOI: 10.1016/s0046-8177(98)90066-1. View

17.

Vigne J, Halburnt L, Skinner M . Characterization of bovine ovarian surface epithelium and stromal cells: identification of secreted proteins. Biol Reprod. 1994; 51(6):1213-21. DOI: 10.1095/biolreprod51.6.1213. View

18.

Lassus H, Sihto H, Leminen A, Nordling S, Joensuu H, Nupponen N . Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma. Br J Cancer. 2004; 91(12):2048-55. PMC: 2409787. DOI: 10.1038/sj.bjc.6602252. View